Brentuximab 50mg
Product Overview
| Generic Name | Brentuximab 50mg |
| Brand Name(s) | Biosimilar Brentuximab 50mg |
| Category | Antibodies, monoclonal |
| Form | IV lyophilized injection vials |
| Strength | 50 mg/vial |
| Therapeutic Class | Antibody–drug conjugate; |
| ATC Code | L01FX05 |
Manufacturing & Regulatory
| Manufacturer | Seagen, Takeda |
| GMP Compliance | FDA/EMA/WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | 010.000.6085.00 |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | Pack of 25 |
| Shelf Life | 24 months |
| Storage | 2–8 °C, protect from light |
| Incoterms | Ex-works Mex |
| Lead Time | 7 - 10 days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | Upon Request |
Special Notes
Biosimilar version of Adcetris (brentuximab vedotin) Indications/Usage: Hodgkin lymphoma, ALCL, CTCL